Ionis Pharmaceuticals (IONS) Stock

The FDA has approved IONS' Tryngolza, making it the first treatment for FCS to gain approval. This is also the first drug that the company fully owns to receive marketing authorization.

The U.S. Food and Drug Administration has given the green light to a drug from Ionis Pharmaceuticals for a rare genetic condition, marking it as the company's first fully-owned medication, according to the health regulator's website on Thursday.

Analysts' average price targets for Ionis Pharmaceuticals (IONS) suggest a potential increase of 55.9% in the stock's value. Although this popular measure hasn't always been very reliable, a strong consensus among analysts in increasing earnings forecasts does suggest a positive outlook for the stock.

Ionis Pharmaceuticals (IONS) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced on November 7, 2024, that its management will take part in discussions at several upcoming investor conferences. These include the Guggenheim's Inaugural Healthcare Conference and the UBS Global Healthcare Conference, both on November 13, 2024, as well as other events throughout December. You can watch these presentations live on the Investors & Media section of the Ionis website.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will hold its Q3 2024 Earnings Conference Call on November 6, 2024, at 11:30 AM ET. Key company participants include Wade Walke, Brett Monia, and Beth Hougen, among others. The call will also feature analysts from various financial institutions, and it is being recorded for future reference.

The main figures for Ionis Pharmaceuticals (IONS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be helpful to compare some important metrics with Wall Street predictions and the results from the same period last year.

Ionis Pharmaceuticals (IONS) reported a quarterly loss of $0.95 per share, which is better than the Zacks Consensus Estimate of a $1.16 loss. This is an improvement compared to a loss of $1.03 per share from the same period last year.

The U.S. launch of WAINUA TM is going well, and it has already been approved in the UK, with a positive opinion from the CHMP for Olezarsen FCS. The PDUFA dates are set for December 19, 2024, for Olezarsen and August 21, 2025, for Donidalorsen, which is currently undergoing EU regulatory submission. Ionis Pharmaceuticals, Inc. announced its third-quarter financial results for 2024 and is on track to meet its financial guidance for the year.